Goldschmidt, H. (2018). Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: Secondary analysis of the phase 3 ENDEAVOR study. Leukemia and lymphoma, 59(6), . https://doi.org/10.1080/10428194.2017.1376743
Chicago-Zitierstil (17. Ausg.)Goldschmidt, Hartmut. "Carfilzomib-dexamethasone Versus Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of the Phase 3 ENDEAVOR Study." Leukemia and Lymphoma 59, no. 6 (2018). https://doi.org/10.1080/10428194.2017.1376743.
MLA-Zitierstil (9. Ausg.)Goldschmidt, Hartmut. "Carfilzomib-dexamethasone Versus Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of the Phase 3 ENDEAVOR Study." Leukemia and Lymphoma, vol. 59, no. 6, 2018, https://doi.org/10.1080/10428194.2017.1376743.